A zonal comparison of MIB1-Ki67 immunoreactivity in benign and malignant melanocytic lesions

American Journal of Dermatopathology

Volumn 22, Issue 6, 2000, Pages 489-495

  Li, Ling Xi L ^a,b   Crotty, Kerry A ^a,b   McCarthy, Stanley W ^b   Palmer, Allan A ^b   Kril, Jillian J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Ki67; Malignancy; Malignant melanoma; Melanocytic nevi; MIB1; Proliferating; Spitz nevi

Indexed keywords

KI 67 ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; DIFFERENTIAL DIAGNOSIS; DISCRIMINANT ANALYSIS; DISEASE CLASSIFICATION; DISEASE MARKER; DYSPLASTIC NEVUS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; JUVENILE MELANOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEVUS; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ANTIGENS, NUCLEAR; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MELANOMA; MIDDLE AGED; NEVUS, EPITHELIOID AND SPINDLE CELL; NEVUS, PIGMENTED; NUCLEAR PROTEINS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034525141     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000372-200012000-00002     Document Type: Article

References (47)

1. How consistent are dermatopathologists in reading early malignant melanomas and lesions "precursor" to them?
2. Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists
3. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67
4. Nuclear size and shape parameters correlate with proliferative activity in cutaneous melanocytic tumours
5. Monoclonal antibody Ki-67: Its use in histopathology
6. Review: Assessment of cell proliferation in histologic material
7. The assessment of cellular proliferation by immunohistochemistry: A view of currently available methods and their applications
8. Tumor cell growth fractions in human malignant melanomas and the correlation to histopathologic tumor grading
9. Proliferative activity of cutaneous melanocytic tumors defined by Ki-67 monoclonal antibody: A quantitative immunohistochemical study
10. Immunohistologic evidence for the malignant potential of congenital melanocytic nevi
11. Ki67 antigen expression correlates with tumour progression and HLA-DR antigen expression in melanocytic lesions
12. Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki67 monoclonal antibodies in melanocytic skin lesions
13. Ki67-structure, function, and new antibodies
14. New Ki-67-equivalent murine monoclonal antibodies (MIB1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three base pair repetitive elements encoding for the Ki-67 epitope
15. Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues
16. Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1
17. Adjuvant role of MIB1 index in differentiating serous ovarian tumors - Preliminary report
18. Assessment of proliferative activity using the MIB1 antibody helps to distinguish polymorphous low grade adenocarcinoma from adenoid cystic carcinoma of salivary glands
19. Ki-67 expression in vulvar carcinoma
20. Usefulness of MIB1 monoclonal antibody in assessing the proliferative index in human bladder carcinoma: Comparison with Ki-67 antibody
21. MIB1 staining index and scoring of histologic features in meningioma. Indicators for the prediction of biologic potential and postoperative management
22. Prognostic value of Ki67 antigen expression in basal cell carcinomas
23. The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer
24. Ki-67 as a prognostic marker in adenoid cystic carcinoma assessed with the monoclonal antibody MIB1 in paraffin sections
25. The combined evaluation of p53 accumulation and of Ki-67 (MIB1) labelling index provides independent information on overall survival of ovarian carcinoma patients
26. Cell proliferation measured by MIB1 and timing of surgery for breast cancer
27. Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi
28. Utility of a proliferation marker in distinguishing between benign naevocellular naevi and naevocellular-naevus like lesions with malignant properties
29. Nevoid malignant melanoma: Morphologic patterns and immunohistochemical reactivity
30. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma
31. Diagnostic impact of nuclear DNA content and proliferative activity in benign and malignant melanocytic lesions
32. Proliferation marker Ki-S5 as a diagnostic tool in melanocytic lesions
33. Immunohistochemical markers for distinguishing Spitz naevi from malignant melanomas
34. Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors
35. Cyclin D1 overexpression in Spitz nevi: An immunohistochemical study
36. Histologic criteria for the diagnosis of superficial spreading malignant melanoma: Formulated on the basis of proven metastatic lesions
37. Malignant melanoma in childhood: A clinicopathologic study of 13 cases and comparison with Spitz naevi
38. Method of melanin bleaching in MIB1-Ki67 immunostaining of pigmented lesions: A quantitative evaluation in malignant melanomas
39. The Ki67 antigen in primary human melanomas - Its relationship to mitotic rate and tumour thickness and its stability
40. KI 67 immunostaining in melanocytic skin tumours. Correlation with histologic parameters
41. Nucleolar organizer regions (AgNOR) and Ki-67 immunoreactivity in cutaneous melanocytic lesions
42. Spindle and epithelioid cell naevi in children and adults
43. The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma